Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Notes Payables (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Notes Payables for 4 consecutive years, with $813.3 million as the latest value for Q3 2025.

  • Quarterly Notes Payables changed N/A to $813.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $813.3 million through Sep 2025, changed N/A year-over-year, with the annual reading at $851.5 million for FY2024, N/A changed from the prior year.
  • Notes Payables for Q3 2025 was $813.3 million at BeOne Medicines, down from $851.5 million in the prior quarter.
  • The five-year high for Notes Payables was $851.5 million in Q4 2024, with the low at $813.3 million in Q3 2025.